❌

Reading view

↗️

Burning Rock's OncoGuideβ„’ OncoScreenβ„’ Plus CDx System Now Approved in Japan as a Companion Diagnostic for Capivasertib in Breast Cancer

βœ‡Burning Rock Biotech Limited News Releases
By: Burning Rock Biotech Limited News Releases
TOKYO and GUANGZHOU, China, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd. (Riken Genesis) and Burning Rock Biotech Limited (NASDAQ: BNR, β€œBurning Rock”) today announced that theΒ OncoGuideβ„’ OncoScreenβ„’ Plus CDx System based on OncoScreenβ„’ Plus to be used as a companion diagnostic for
  •  
  • ↗️
There are no more articles
❌